IP Library Granted Patent US 10,517,908
Granted Patent B2
US 10,517,908 · App. 15/237,496 · Granted Dec 31, 2019

Therapeutic bacteriophage compositions

Inventors: Karen Joy Shaw (Glen Allen, VA); Sandra P. Morales (Sydney, AU); Gillian Mearns (Sydney, AU); Deborah A. Rankin (Sydney, AU); Frenk Smrekar (Ljubjlana, SI)
Assignee: ARMATA PHARMACEUTICALS, INC.
A61K35/76A01N63/00A61L15/40C12N7/00C12N2795/00021C12N2795/00031C12N2795/00032
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,517,908
App. No.
15/237,496
Granted
Dec 31, 2019
Kind
B2
Abstract

The present invention relates to a bacteriophage composition comprising one or more (suitably two or more, or three) bacteriophages selected from Sa87, J-Sa36, Sa83, J-Sa37, or mutants thereof, use of the same for medical or non-medical applications, kits, bandage, and wound dressing comprising the same.

Claims (21)

1. A method of treating a Staphylococcus aureus bacterial infection, comprising administering a bacteriophage composition comprising one or more bacteriophages that infect and lyse Staphylococcus aureus selected from Sa87, J-Sa36, and Sa83.

2. A method of treating a pulmonary bacterial infection in a subject comprising administering a bacteriophage composition comprising one or more bacteriophages that infect and lyse Staphylococcus aureus selected from Sa87, J-Sa36, and Sa83 to the subject, wherein the bacterial infection comprises Staphylococcus aureus.

3. The method according to claim 1 , further comprising administering an antibiotic to the subject.

4. A method of killing Staphylococcus aureus bacteria on a surface, said method comprising applying a bacteriophage composition comprising one or more bacteriophages that infect and lyse Staphylococcus aureus selected from Sa87, J-Sa36, and Sa83 to the surface.

5. The method according to claim 4 , wherein the surface is the skin of a mammal, equipment, bedding, furniture, walls, floors, or combinations thereof.

6. A non-medical method of killing Staphylococcus aureus bacteria comprising applying to a food product or a crop a bacteriophage composition comprising one or more bacteriophages that infect and lyse Staphylococcus aureus selected from Sa87, J-Sa36, and Sa83.

7. The method according to claim 2 , further comprising administering an antibiotic to the subject.

8. The method according to claim 1 , wherein the bacteriophage composition comprises Sa87, J-Sa36, and Sa83.

9. The method according to claim 1 , wherein the bacteriophage composition consists essentially of Sa87, J-Sa36, and Sa83.

10. The method according to claim 2 , wherein the bacteriophage composition comprises Sa87, J-Sa36, and Sa83.

11. The method according to claim 2 , wherein the bacteriophage composition consists essentially of Sa87, J-Sa36, and Sa83.

12. The method according to claim 4 , wherein the bacteriophage composition comprises Sa87, J-Sa36, and Sa83.

13. The method according to claim 4 , wherein the bacteriophage composition consists essentially of Sa87, J-Sa36, and Sa83.

14. The method according to claim 4 , further comprising applying an antibiotic.

15. The method according to claim 6 , wherein the bacteriophage composition comprises Sa87, J-Sa36, and Sa83.

16. The method according to claim 6 , wherein the bacteriophage composition consists essentially of Sa87, J-Sa36, and Sa83.

17. The method according to claim 6 , further comprising use of an antibiotic.

18. The method according to claim 3 , wherein the antibiotic is a chemical antibiotic.

19. The method according to claim 7 , wherein the antibiotic is a chemical antibiotic.

20. The method according to claim 14 , wherein the antibiotic is a chemical antibiotic.

21. The method according to claim 17 , wherein the antibiotic is a chemical antibiotic.

Assignments (9)
SECURITY INTEREST Recorded May 20, 2026
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 074715/0208 →
SECURITY INTEREST Recorded Aug 14, 2025
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 072025/0567 →
SECURITY INTEREST Recorded Mar 17, 2025
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 070532/0979 →
SECURITY INTEREST Recorded Mar 5, 2024
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC.; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 066657/0409 →
SECURITY INTEREST Recorded Jul 14, 2023
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC.; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 064262/0958 →
SECURITY INTEREST Recorded Feb 17, 2023
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC.; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 062733/0983 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2019
From: MORALES, SANDRA P.; MEARNS, GILLIAN; RANKIN, DEBORAH A.; SMREKAR, FRENK
To: ARMATA PHARMACEUTICALS, INC.
Reel/Frame 049865/0891 →
CHANGE OF NAME Recorded Jul 3, 2019
From: AMPLIPHI BIOSCIENCES CORPORATION
To: ARMATA PHARMACEUTICALS, INC.
Reel/Frame 049678/0137 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2019
From: SHAW, KAREN JOY
To: AMPLIPHI BIOSCIENCES CORPORATION
Reel/Frame 048806/0675 →
Continuity (2)
Provisional Application 62204915 · Aug 13, 2015
Related Publication 20170065649A1 · Mar 9, 2017
Cited By (2)
US 12,239,677 US 12,503,687